GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 OutlookZacks Investment Research • 02/04/26
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT BuyoutZacks Investment Research • 01/21/26
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026Business Wire • 01/21/26
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSKGlobeNewsWire • 01/20/26
GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics BuyoutInvestors Business Daily • 01/20/26
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 MillionBusiness Wire • 01/20/26
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drugMarket Watch • 01/20/26
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ TechnologyPRNewsWire • 01/20/26
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26